Janus Henderson Group plc Reports 9.99% Stake in Forte Biosciences, Inc.

Janus Henderson Group plc has filed a Schedule 13G/A reporting a significant new position in Forte Biosciences, Inc. (FBRX). As of March 31, 2026, the filer beneficially owns 1,387,178 shares of common stock, representing a 9.99% ownership stake in the company. This filing marks an increase from a previously reported 0% position. Janus Henderson Group plc serves as the parent holding company for several investment advisers, including Janus Henderson Investors US LLC, which exercise shared voting and dispositive power over these shares on behalf of managed portfolios. Additionally, the filing notes the existence of 299,798 pre-funded warrants; however, these are subject to a blocker preventing exercise if it would result in ownership exceeding the 9.99% threshold. Among the managed accounts, the Janus Henderson Biotech Innovation Master Fund Ltd. is identified as having a right to dividends or sales proceeds exceeding 5% of the class. The acquisition was made in the ordinary course of business without the intent to influence control.